Surgical Oncology
Volume 19, Issue 2 , Pages 49-51 , June 2010

Evolution of cancer survival analysis

  • Shunzo Maetani

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +81 743 63 5611; fax: +81 743 63 1530.

Received 4 March 2010

References 

  1. Cox DR. Regression model and life-table. J Roy Statist Soc. 1972;B34:187–220
  2. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: part II. Analysis and examples. Br J Cancer. 1977;35:1–39
  3. Freireich EJ, Gehan E, Frei E, Schroeder LR, Wolman IJ, Anbari R, et al. The effect of 6-mercaptopurine on the duration of steroid-induced remission in acute leukemia: a model for evaluation of other potentially useful therapy. Blood. 1963;21:699–716
  4. D’angio GJ, Vietti TJ. Old man river: the flow of pediatric oncology. Hematol Oncol Clin North Am. 2001;15:599–607
  5. Thomas A. Joe Burchanal and the birth of combination chemotherapy. Br J Haematol. 2006;133:493–503
  6. Cox DR, Oakes D. Analysis of survival data. 1st ed.. London: Chapman and Hall; 1984;
  7. Boag JW. Maximum likelihood estimates of the proportion of patients cured by cancer therapy. J Roy Statist Soc. 1949;11B:15–53
  8. Gamel JW, Vogel R. Comparison of parametric and non-parametric survival methods using simulated clinical trials. Stat Med. 1997;16:1629–1643
  9. Sposto R. Cure model analysis in cancer: an application to data from the children’s cancer group. Stat Med. 2002;21:293–312
  10. Frankel P, Longmate J. Parametric models for accelerated and long-term survival: a comment on proportional hazards. Stat Med. 2002;21:3279–3289
  11. Maetani S, Segawa Y, Banja H, Obayashi H, Nishikawa T, Hasegawa S, et al. Simulation of randomized controlled trials for cancer therapy using the Boag model and the competing risk model. Tenri Medical Bulletin. 2008;11:22–40
  12. Gamel JW, McLEAN IW. A stable, multivariate extension of the log-normal survival model. Comput Biomed Res. 1994;27:148–155
  13. Maetani S, Onodera H, Nishikawa T. Long-term cure in surgery for extrarectal pelvic recurrence of rectal cancer. Dis Colon Rectum. 2007;50:1588–67
  14. Gamel JW, Vogel RL, Valagussa PV, Bonadonna G. Parametric survival analysis of adjuvant therapy for stage II breast cancer. Cancer. 1994;74:2483–2490
  15. Nishikawa T, Maetani S. Evaluation of intensive adjuvant chemotherapy in gastric cancer using life expectancy compared with logrank test as a measure of survival benefit. Ann Surg Oncol. 2007;14:348–354
  16. Gamel JW, Bonaddona G, Valagussa P, Edwards MJ. Refined measurement of outcome for adjuvant breast carcinoma therapy. Cancer. 2003;97:1139–1146
  17. Maetani S, Nakajima T, Nishikawa T. Parametric mean survival analysis in gastric cancer patients. Med Decis Making. 2004;24:131–141
  18. Gross AJ, Clark VA. Survival distributions: reliability applications in the biomedical sciences. New York: Johns Wiley & Sons; 1975;

PII: S0960-7404(10)00028-9

doi: 10.1016/j.suronc.2010.03.002

Surgical Oncology
Volume 19, Issue 2 , Pages 49-51 , June 2010

Article Tools

* Image Usage & Resolution